RBRupert M. Bauersachs

Rupert M. Bauersachs

*This is an algorithmically generated author record based on publicly available information.

Rupert M. Bauersachs has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry

    by Giancarlo Agnelli, Anselm K. Gitt, Rupert Bauersachs, Eva-Maria Fronk, Petra Laeis, Patrick Mismetti, Manuel Monreal, Stefan N. Willich, Wolf-Peter Wolf, Alexander T. Cohen

    Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influencing treatment pathways, patient satisfaction, quality of life (QoL), and utilization of health care resources and the corresponding costs. The PREFER in VTE registry has been designed to address this and to understand medical care and needs as well as potential gaps for improvement. The PREFER in VTE registry was a prospective, observational, multicenter study conducted in seven European countries including Austria, France Germany, Italy, Spain, Switzerland, and the UK to assess the characteristics and the management of patients with VTE, the use of health care resources, and to provide data to estimate the costs for 12 months treatment following a first-time and/or recurrent VTE diagnosed in hospitals or specialized or primary care centers. In addition, existing anticoagulant treatment patterns, patient pathways, clinical outcomes, treatment satisfaction, and health related QoL were documented. The centers were chosen to reflect the care environment in which patients with VTE are managed in each of the participating countries. Patients were eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, pulmonary embolism or both. After the baseline visit at the time of the acute VTE event, further follow-up documentations occurred at 1, 3, 6 and 12 months. Follow-up data was collected by either routinely scheduled visits or by telephone calls. Overall, 381 centers participated, which enrolled 3,545 patients during an observational period of 1 year. The PREFER in VTE registry will provide valuable insights into the characteristics of patients with VTE and their acute and mid-term management, as well as into drug utilization and the use of health care resources in acute first-time and/or recurrent VTE across Europe in clinical practice. Registered in DRKS register, ID number: DRKS00004795


  • Deep Vein Thrombosis

    by Rupert M. Bauersachs, Bernd Krabbe

  • Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial

    by Martin H. Prins, Luke Bamber, Stefan J. Cano, Maria Y. Wang, Petra Erkens, Rupert Bauersachs, Anthonie W.A. Lensing


  • Deep Vein Thrombosis

    by Rupert M. Bauersachs, Bernd Krabbe

  • Open Access

    CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients

    by Agnes Yy Lee, Rupert Bauersachs, Mette S Janas, Mikala F Jarner, Pieter W Kamphuisen, Guy Meyer, Alok A Khorana

    Low-molecular-weight heparin (LMWH) is recommended and commonly used for extended treatment of cancer-associated thrombosis (CAT), but its superiority over warfarin has been demonstrated in only one randomised study. We report here the rationale, design and a priori analysis plans of Comparison of Acute Treatments in Cancer Haemostasis (CATCH; NCT01130025), a multinational, Phase III, open-label, randomised controlled trial comparing tinzaparin with warfarin for extended treatment of CAT. The primary objective is to assess the efficacy of tinzaparin in preventing recurrent venous thromboembolism (VTE) in patients with active cancer and acute, symptomatic proximal deep vein thrombosis and/or pulmonary embolism. The secondary objectives are to determine: safety of tinzaparin given over 6 months; clinical and laboratory markers for recurrent VTE and/or major bleeding; 6-month overall mortality; incidence and severity of post-thrombotic syndrome; patient-reported quality of life; and healthcare resource utilisation. Nine hundred patients are randomised to receive tinzaparin 175 IU/kg once daily for 6 months or initial tinzaparin 175 IU/kg once daily for 5–10 days and dose-adjusted warfarin (target INR 2.0–3.0) for 6 months. The primary composite outcome is time to recurrent VTE, including incidental VTE and fatal pulmonary embolism. All patients are followed up to 6 months or death, whichever comes sooner. Blinded adjudication will be performed for all reported VTE, bleeding events and causes of death. Efficacy will be analysed using centrally adjudicated results of all patients according to intention-to-treat analysis. An independent Data Safety Monitoring Board is reviewing data at regular intervals and an interim analysis is planned after 450 patients have completed the study. The results will add significantly to the knowledge of the efficacy, safety and cost effectiveness of tinzaparin in the prevention of recurrent VTE in patients with cancer and thrombosis. Prospective data will emerge on the clinical significance of incidental VTE and risk stratification in patients with CAT. Results on post-thrombotic syndrome, quality of life and healthcare resource utilisation will inform decision makers on how to secure better patient care. If tinzaparin is shown to be more effective than warfarin, CATCH will provide valuable confirmatory data to support the use of the LMWH tinzaparin for extended treatment of CAT.


  • Diagnosis and treatment of superficial vein thrombosis

    by R. M. Bauersachs

    Summary: Superficial vein thrombosis (SVT) is a common disease, characterized by an inflammatory- thrombotic process in a superficial vein. Typical clinical findings are pain and a warm, tender, reddish cord along the vein. Until recently, no reliable epidemiological data were available. The incidence is estimated to be higher than that of deep-vein thrombosis (DVT) (1/1000). SVT shares many risk factors with DVT, but affects twice as many women than men and frequently occurs in varicose veins. Clinically, SVT extension is commonly underestimated, and patients may have asymptomatic DVT. Therefore, ultrasound assessment and exclusion of DVT is essential. Risk factors for concomitant DVT are recent hospitalization, immobilization, autoimmune disorders, age > 75 years, prior VTE, cancer and SVT in non-varicose veins. Even though most patients with isolated SVT (without concomitant DVT or PE) are commonly treated with anticoagulation for a median of 15 days, about 8% experience symptomatic thromboembolic complications within three months. Risk factors for occurrence of complications are male gender, history of VTE, cancer, SVT in a non-varicose vein or SVT involving the sapheno-femoral junction (SFJ). As evidence supporting treatment of isolated SVT was sparse and of poor quality, the large, randomized, double-blind, placebocontrolled CALISTO trial was initiated assessing the effect of fondaparinux on symptomatic outcomes in isolated SVT. This study showed that, compared with placebo, 2.5 mg fondaparinux given for 45 days reduced the risk of symptomatic thromboembolic complications by 85% without increasing bleeding. Based on CALISTO and other observational studies, evidence-based recommendations can be made for the majority of SVT patients. Further studies can now be performed in higher risk patients to address unresolved issues.


  • Neues zur Therapie oberflächlicher Venenthrombosen und extrakranieller Karotisstenosen

    by R M Bauersachs, P J Kuhlencordt

    Die oberflächliche Venenthrombose (OVT) tritt mindestens so häufig auf wie eine tiefe Venenthrombose (TVT) und hat ähnliche Risikofaktoren wie die venöse Thromboembolie. Die CALISTO-Studie liefert erstmals konkrete Empfehlungen zur medikamentösen Behandlung einer OVT: Vor Therapiebeginn muss zunächst eine TVT ausgeschlossen und die proximale Ausdehnung der OVT bestimmt werden. Bei einer Ausdehnung näher als 3 cm an das tiefe Venensystem sollte wie eine TVT behandelt werden. Unter bestimmten Voraussetzungen ist bei akuter, symptomatischer OVT eine Therapie mit Fondaparinux indiziert. Außerdem ist eine konsequente Kompressionstherapie zu empfehlen. Für die Behandlung einer extrakraniellen Karotisstenose kommen eine chirurgische Thrombendarteriektomie oder ein endovaskuläres Stenting der A. carotis in Frage. Studien, die beide Verfahren miteinander vergleichen, lassen keine eindeutige Schlussfolgerung hinsichtlich der Gleichwertigkeit zu. Angesichts der vorliegenden Daten scheint der adäquaten Patientenselektion (Symptomatik, Komorbiditäten, Alter, anatomische Voraussetzungen) im interdisziplinären Gespräch eine herausragende Bedeutung zuzukommen. Völlig offen bleibt die Frage, ob Patienten mit hochgradiger asymptomatischer Karotisstenose unter einer modernen Sekundärprophylaxe grundsätzlich oder nur in zu definierenden Einzelfällen revaskularisiert werden sollten. Superficial vein thrombosis (SVT) occurs at least as frequent as deep vein thrombosis (DVT), and shares common risk factors with venous thromboembolism. The CALISTO trial was the first to provide specific recommendations for the pharmacologic treatment of SVT. Before treatment is initiated, an accompanying DVT must be excluded and the proximal extension of the SVT assessed. If the proximal extension of the thrombus is closer than 3 cm towards the deep vein system, it should be treated like DVT. Under certain conditions treatment with fondaparinux is indicated in acute symptomatic SVT. Furthermore, compression treatment is recommended. Extracranial carotid artery stenosis can be treated by either surgical thrombarterectomy or catheter based endovascular stent implantation. Trials comparing the two methods have not provided conclusive results on whether the two strategies are equally safe and effective. Considering the latest data from RCTs, careful patient selection (symptoms, comorbidities, age, anatomy, re-stenosis) including individual interdisciplinary discussion appears of ample importance. To date no information is available on whether patients with asymptomatic high grade carotid stenosis receiving „best medical therapy” should be considered for revascularisation in general or only in selected circumstances.

  • Die CALISTO-Studie

    by R. M. Bauersachs

    Zusammenfassung: Die oberflächige Venenthrombose (OVT) tritt häufiger als die tiefe Venenthrombose (TVT) auf und betrifft Frauen doppelt so häufig wie Männer. Bei Patienten mit einer isolierten OVT, d.h. ohne gleichzeitige TVT oder Lungenembolie (LE), besteht ein erhöhtes Risiko für thromboembolische Komplikationen. Bislang gab es nur wenige randomisierte Studien zur OVT, und keine einzige mit ausschließlich klinischen Endpunkten. Daher war das Ziel der CALISTO-Studie, mit einem randomisierten, doppelt-blinden, placebo-kontrollierten Design die Wirksamkeit und Sicherheit einer 45-tägigen Behandlung mit Fondaparinux bei 3 002 Patienten mit isolierter OVT zu untersuchen im Hinblick auf klinische thromboembolische Endpunkte (Kombination von Tod, symptomatischer VTE, symptomatische Ausdehnung der OVT in die Crosse oder symptomatische Rezidive). Der primäre Endpunkt trat bei 0,9 % unter Fondaparinux, und bei 5,9 % unter Plazebo auf (RRR 85 %; 74–92 %; P<0,001). Es gab in jeder Gruppe jeweils eine schwere Blutung, ernste unerwünschte Ereignisse waren in beiden Gruppen vergleichbar (0,7 versus 1,1 % unter Plazebo). Die einmal tägliche Gabe von 2,5 mg Fondaparinux über 45 Tage war effektiv und sicher in der Behand-lung von Patienten mit akuter, symptomatischer, isolierter OVT und hatte im Vergleich zu Placebo keine schwerwiegenden Nebenwirkungen. Es handelt sich damit um die erste evidenzbasierte antithrombotische Therapie der OVT.